

# 1 Thymic epithelial organoids mediate T cell 2 development

3  
4  
5 Tania Hübscher<sup>1</sup>, L. Francisco Lorenzo-Martín<sup>1</sup>, Thomas Barthlott<sup>2</sup>, Lucie Tillard<sup>1</sup>, Jakob J.  
6 Langer<sup>1</sup>, Paul Rouse<sup>3</sup>, C. Clare Blackburn<sup>3</sup>, Georg Holländer<sup>2,4,5</sup> and Matthias P. Lutolf<sup>1,7,\*</sup>

7  
8 <sup>1</sup> Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences  
9 and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne,  
10 Switzerland

11 <sup>2</sup> Department of Biomedicine, University of Basel, Basel, Switzerland

12 <sup>3</sup> Centre for Regeneration, Institute for Repair and Regeneration, School of Biological  
13 Sciences, University of Edinburgh, Edinburgh, UK

14 <sup>4</sup> Department of Paediatrics and Institute of Developmental and Regenerative Medicine,  
15 University of Oxford, Oxford, UK

16 <sup>5</sup> Pediatric Immunology, Department of Biomedicine, University of Basel and University  
17 Children's Hospital Basel, Basel, Switzerland

18 <sup>6</sup> Department of Biosystems Science and Engineering, Eidgenössische Technische  
19 Hochschule Zürich (ETHZ), Basel, Switzerland

20 <sup>7</sup> Institute of Human Biology (IHB), Pharma Research and Early Development, Roche  
21 Innovation Center Basel, Basel, Switzerland

22

23 \*Corresponding author. Email: [matthias.lutolf@epfl.ch](mailto:matthias.lutolf@epfl.ch)

24

25

## 26 **Abstract**

27 **Although the advent of organoids opened unprecedented perspectives for basic and**  
28 **translational research, immune system-related organoids remain largely**  
29 **underdeveloped. Here we established organoids from the thymus, the lymphoid organ**  
30 **responsible for T cell development. We identified conditions enabling thymic epithelial**  
31 **progenitor cell proliferation and development into organoids with in vivo-like**  
32 **transcriptional profiles and diverse cell populations. Contrary to two-dimensional**  
33 **cultures, thymic epithelial organoids maintained thymus functionality in vitro and**  
34 **mediated physiological T cell development upon reaggregation with T cell progenitors.**  
35 **The reaggregates showed in vivo-like epithelial diversity and ability to attract T cell**  
36 **progenitors. Thymic epithelial organoids provide new opportunities to study TEC**  
37 **biology and T cell development in vitro, pave the way for future thymic regeneration**  
38 **strategies and are the first organoids originating from the stromal compartment of a**  
39 **lymphoid organ.**

40

41 **Summary statement: Establishment of organoids from the epithelial cells of the thymus**  
42 **which resemble their in vivo counterpart and have thymopoietic ability in reaggregate**  
43 **culture.**

44 **Keywords: Thymus, Organoids, Thymic epithelial cells, Thymopoiesis**

## 45 INTRODUCTION

46 Over the past two decades, organoids have revolutionized the field of stem cell biology.  
47 Recapitulating key elements of the architecture, multicellularity, or function of their native  
48 organs on a smaller scale (Rossi et al., 2018), organoids have opened up unprecedented  
49 opportunities for personalized medicine. These three-dimensional (3D) structures derived from  
50 stem or progenitor cells have been established from a wide variety of organs, particularly of  
51 the endodermal lineage (Rossi et al., 2018). However, despite the availability of organotypic  
52 cultures (e.g. tissue explants (Anderson and Jenkinson, 1998; Owen and Ritter, 1969) and  
53 reaggregates (Giger et al., 2022; Jenkinson et al., 1992; Wagar et al., 2021)) or engineering  
54 methods (Kim et al., 2019) (e.g. scaffolds (Asnaghi et al., 2021; Bourgine et al., 2018;  
55 Campinoti et al., 2020; Fan et al., 2015; Hun et al., 2016; Poznansky et al., 2000; Purwada  
56 and Singh, 2017) and organ-on-a-chip (Goyal et al., 2022)), bona fide immune system-related  
57 organoids are considerably underdeveloped. Modelling lymphoid organs is indeed particularly  
58 challenging, largely due to the intricate crosstalk between immune and stromal cells required  
59 for organ development and function (Anderson and Jenkinson, 1998).

60 One essential organ for adaptive immunity is the thymus as it functions as the site of T cell  
61 development. In the thymus, T cell progenitors undergo lineage commitment and various  
62 selection processes to ensure the formation of a diverse, functional, and self-tolerant T cell  
63 repertoire, essential for effective immune protection. The instruction of the developing T cells  
64 (termed thymocytes) is mostly mediated by thymic epithelial cells (TECs). These stromal cells  
65 originate from the pharyngeal endoderm and can be subdivided into cortical and medullary  
66 lineages, which mediate successive stages of T cell development.

67 The essential thymopoietic ability of TECs is however mostly lost in vitro, as traditional two-  
68 dimensional (2D) cultures fail to maintain their functionality (Anderson and Jenkinson, 1998;  
69 Anderson et al., 1998; Mohtashami and Zúñiga-Pflücker, 2006). Alternative approaches  
70 employing OP9 or MS5 cell lines have been developed to circumvent this limitation and study  
71 T cell development in vitro (Montel-Hagen et al., 2020; Seet et al., 2017), but the absence of  
72 TECs still prevents physiological modelling of T cell selection processes. Other efforts focused  
73 on obtaining TECs from pluripotent stem cells (Lai and Jin, 2009; Parent et al., 2013; Ramos  
74 et al., 2022; Sun et al., 2013) or through direct reprogramming (Bredenkamp et al., 2014), but  
75 these cells largely rely on in vivo grafting to reveal thymopoietic functionality. It was also shown  
76 that TECs can form colonies in Matrigel, but these cultures still require feeder cells and their  
77 functionality was not demonstrated (Lepletier et al., 2019; Meireles et al., 2017; Wong et al.,  
78 2014). Thus, currently the only existing way to preserve TEC functionality in vitro is through  
79 (reaggregate) thymic organ cultures, which are organotypic 3D cultures containing different  
80 cell types.

81 Here, in light of what has been achieved for other endoderm-derived epithelia, we postulated  
82 that TECs could be grown independently of other cell types as 3D organoids in an extracellular  
83 matrix-based hydrogel. We identified culture conditions allowing TECs to form organoids  
84 mirroring to some extent the native tissue, and proved their functionality through their ability to  
85 mediate T cell development upon reaggregation with T cell progenitors. This work establishes  
86 the first thymic epithelial organoids with in vitro thymopoietic ability and is generally the first  
87 demonstration of organoids originating from the stromal compartment of a lymphoid organ.

88

## 89 **RESULTS AND DISCUSSION**

### 90 **Thymic epithelial cells grow and maintain marker expression in defined organoid 91 culture conditions**

92 To establish thymic epithelial organoids, we followed the approach used for other endodermal  
93 organs, which included dissociating the tissue, sorting the cells of interest, and seeding them  
94 in a basement membrane-rich hydrogel (Matrigel) (Fig. 1A and Fig. S1 A). Since organoids  
95 mostly develop from stem or progenitor cells, we focused on the embryonic thymus due to its  
96 higher abundance of thymic epithelial progenitor cells compared to the adult organ (Baran-  
97 Gale et al., 2020; Kadouri et al., 2020). Although previous attempts to culture TECs often used  
98 serum-containing medium (Bonfanti et al., 2010; Campinoti et al., 2020; Wong et al., 2014),  
99 we opted for defined organoid basal medium and investigated factors that could promote TEC  
100 growth. We hypothesized that mesenchyme-derived factors that have been shown to influence  
101 TEC populations both in vivo and in vitro (Alawam et al., 2020; Boehm and Swann, 2013;  
102 Chaudhry et al., 2016; James et al., 2021) could also be important for TEC growth in organoid  
103 cultures. Among these factors, we found FGF7 of particular interest, as it has recently been  
104 shown to sustain the expansion of thymic microenvironments without exhausting the epithelial  
105 progenitor pools in vivo (Nusser et al., 2022). Using E16.5 embryonic thymi, we showed that  
106 while sorted TECs failed to grow in organoid basal medium, adding FGF7 to the culture  
107 supported organoid formation (Fig. 1, B and C). To monitor organoid development, we  
108 performed time-lapse imaging from the time of seeding (Fig. 1D and Movie 1) and found that  
109 most organoids were derived from single cells with stem/progenitor properties.


110 Immunostaining confirmed that organoids were generated by thymus-derived EpCAM-positive  
111 cells (Fig. 1E). Single cells formed small organoids in which a large majority of cells were  
112 positive for Ki67 after 3 days (Fig. 1F), and both proliferating and non-proliferating cells were  
113 present 4 days later (Fig. S1B). To investigate whether these cell populations could  
114 recapitulate TEC diversity, including cortical and medullary types (cTECs and mTECs), we  
115 stained organoids for the cTEC marker Keratin 8 (KRT8), as well as for Keratin 5 (KRT5) and

116 with UEA1 lectin as mTEC markers. Overall, our TEC culture system demonstrated a canonical  
117 feature of organoids in the emergence of different cell types, with varying degrees of KRT5  
118 expression (Fig. 1G) and the presence of both KRT8-positive and UEA1-reactive populations  
119 (Fig. S1C). In addition, at least some organoids were positive for MHCII (Fig. 1H), an important  
120 marker of TEC functionality required for the development of CD4+ T cells (Kadouri et al., 2020).  
121 TEC differentiation, function and maintenance being critically dependent on the transcription  
122 factor *Foxn1* (Žuklys et al., 2016), we further sought to detect transcripts for this master  
123 regulator using RNAscope. Unlike in standard 2D cultures where it is highly downregulated  
124 (Anderson et al., 1998; Mohtashami and Zúñiga-Pflücker, 2006), a clear *Foxn1* expression  
125 could be observed in organoids (Fig. 1I).

126 To benchmark thymic epithelial organoids against standard 2D culture, we performed bulk  
127 RNA sequencing. Unsupervised hierarchical clustering showed the higher transcriptional  
128 similarity of thymic epithelial organoids to freshly extracted TECs (in vivo) than to 2D-cultured  
129 TECs (Fig. 1J, left). Similarly, a differential expression analysis showed that the expression  
130 levels of some key TEC genes, including *Foxn1*, *Dll4* and *Psmb11*, were more similar between  
131 in vivo TECs and thymic epithelial organoids compared to 2D-cultured TECs (Fig. 1J, right).  
132 Conversely, *Il7* and *Cdh1* were maintained in 2D culture as previously reported (Anderson et  
133 al., 1998), and *Ly6a* (a marker of specific TEC subpopulations (Klein et al., 2023)) was  
134 upregulated. Lastly, gene set enrichment analysis performed on organoids at different time  
135 points confirmed the proliferation peak observed with staining (Fig. S1D).

136 Collectively, these findings show that the defined culture conditions identified herein allow  
137 TECs (i) to grow independently of other cell types (ii) to form organoids containing diverse cell  
138 populations and that are transcriptionally similar to in vivo TECs.

139



140

141 **Fig. 1. Thymic epithelial cells grow and maintain marker expression in defined organoid culture**  
142 **conditions.** (A) Schematic of the experimental workflow to isolate, select and culture thymic epithelial  
143 cells (TECs) to obtain organoids. (B) Brightfield images of TECs in organoid culture conditions one day  
144 (D1) and one week (D7) after seeding, in organoid basal medium and in organoid basal medium  
145 supplemented with FGF7. Scale bars, 100µm. (C) Metabolic activity (measured using resazurin) of TECs  
146 cultured in organoid basal medium and in organoid basal medium with FGF7. \*\*: P = 0.0047, \*\*\*: P =  
147 0.0005, ns: P > 0.05 (two-way ANOVA; n = 15 per condition, from 3 mice). Data represent mean ±  
148 standard deviation (SD). (D) One-week time course showing close up brightfield images of sorted TECs  
149 from single cells to multicellular organoids. Scale bars, 10µm. (E) Immunofluorescence image of  
150 individual EpCAM-positive (magenta) TECs immediately after seeding (D0) with nuclei counterstained  
151 using Dapi (grey). Scale bar, 10µm. (F) Immunofluorescence image of organoids three days after  
152 seeding demonstrating that cells undergo proliferation (Ki67 [cyan], Dapi stains nuclei [grey]). Scale  
153 bars, 10µm. (G) Immunofluorescence image of organoids showing different cell populations after one  
154 week in culture, here with medullary cells (KRT5 [red hot]) present in different patterns. Dapi  
155 counterstains nuclei (grey). Scale bar, 10µm. (H) Immunofluorescence image highlighting MHCII  
156 expression (orange) in D7 organoids also stained with KRT8 (cyan) and Dapi (nuclei, grey). Scale bar,  
157 10µm. (I) RNAscope image of organoid at D7 showing *Foxn1* expression (red) with nuclei counterstained  
158 using Spectral Dapi (grey). Scale bar, 10µm. (J) Gene expression profiling. Left: dendrogram (using  
159 hclust) showing clustering of thymic epithelial organoids (Org.) with freshly extracted TECs (In vivo) and  
160 not TECs cultured in 2D (2D). Metrics is complete linkage distance. Right: heatmap displaying key TEC  
161 genes as well as *Cdh1* and *Ly6a* expression for the same three conditions. n = 2 mice per condition.

162

163 **TECs cultured as organoids show in vitro functionality when reaggregated with T cell**  
164 **progenitors**

165 To test the functionality of thymic epithelial organoids (i.e. their ability to mediate T cell  
166 development), we recapitulated the well-known reaggregate fetal thymic organ culture

167 (RFTOC) approach, wherein selected thymic cell populations are reaggregated together and  
168 cultured at the air-liquid interface (Anderson et al., 1993; Jenkinson et al., 1992). To do so, we  
169 dissociated TECs cultured as organoids and reaggregated them with an EpCAM-depleted  
170 single cell suspension obtained from E13.5 thymi. We performed EpCAM-depletion in order to  
171 keep the mesenchymal cells, which have been proven critical for T cell development (Anderson  
172 et al., 1993). We used E13.5 embryonic thymi as source of T cell precursors because they  
173 contain thymocytes at the earliest stages of development, prior to the expression of CD4 and  
174 CD8 (thus referred to as double negative, DN) (Fig. S2A). This allows to easily monitor whether  
175 T cell development happens in the reaggregates. To increase cell number and facilitate  
176 handling, mouse embryonic fibroblasts (MEFs) were also added, as done previously (Sheridan  
177 et al., 2009). We termed the RFTOCs formed with TECs from the organoid cultures organoid  
178 RFTOCs (ORFTOCs) (Fig. 2A).


179 After 6 days in culture, ORFTOCs were dissociated and analyzed by flow cytometry (Fig. S2B).  
180 At this point, thymocytes expressing both CD4 and CD8 (termed double positive, DP) and  
181 constituting a developmental stage following the DN phenotype could be readily detected (Fig.  
182 2, B and C), indicating that organoid-derived TECs mediated physiological progression of  
183 thymocyte maturation. Notably, the proportion of DPs was similar to that observed in cultured  
184 intact thymic lobes (i.e. fetal thymic organ cultures, FTOCs) (Fig. 2, C and D). Conversely,  
185 reaggregating only the EpCAM-depleted fraction of E13.5 thymi and MEFs did not yield DP  
186 thymocytes (Fig. 2, C and D, and Fig. S2C), demonstrating that organoid-derived TECs are  
187 necessary for T cell development in ORFTOCs. Lastly, reaggregates with only organoid-  
188 derived TECs and MEFs served as negative control and did not produce immune (CD45+)  
189 cells (Fig. 2E), as opposite to the other conditions (Fig. S2B, C, D). To corroborate our findings,  
190 we reaggregated organoid-derived TECs with the earliest DN subpopulation (DN1) sorted from  
191 adult mice and MEFs, and could also observe thymocyte development (Fig. S2E). The  
192 developmental kinetics was however faster in ORFTOCs containing E13.5-derived cells, as  
193 expected for first wave early T cell precursors (Rothenberg, 2021).

194 Extending ORFTOC culture period from 6 to 13 days allowed thymocyte maturation to progress  
195 further, as an increased proportion of cells expressed the  $\alpha\beta$  T cell receptor complex (TCR)  
196 (Fig. S2F and Fig. 2F), and differentiated into the separate lineages of CD4+ and CD8+ single  
197 positive (SP) thymocyte, respectively (Fig. S2F). FTOCs were again used as reference (Fig.  
198 S2G) and demonstrated a comparable proportion of mature SP cells (Fig. S2H).

199 As expected for functional TECs, ORFTOCs were positive for *Foxn1* (Fig. 2G).  
200 Morphologically, ORFTOCs also presented similarities to FTOCs, here highlighted by KRT8  
201 and MHCII staining (Fig. 2H). UEA1 reactivity identified sparse medullary cells throughout

202 ORFTOCs (Fig 2, I and J), and CD3 $\epsilon$  staining confirmed the presence of T cells in between  
203 EpCAM-positive epithelial cells (Fig. 2J).

204 In summary, we demonstrated that thymic epithelial organoids maintain their functionality and,  
205 when reaggregated with T cell progenitors, mediate T cell development similarly to intact  
206 thymic lobe cultures.



207  
208 **Fig. 2. TECs cultured as organoids show in vitro functionality when reaggregated with T cell  
209 progenitors. (A)** Schematic of the experimental workflow to generate Organoid Reaggregate Fetal  
210 Thymic Organ Cultures (ORFTOCs) and analyze T cell development. **(B)** Flow cytometry plot showing  
211 T cell development in ORFTOCs after 6 days in culture (D6). Gating strategy is indicated on the left. **(C)**  
212 Proportion of double positive (DP) thymocytes at D6 in ORFTOCs and controls (fetal thymic organ  
213 cultures [FTOCs] and reaggregates containing only mouse embryonic fibroblasts [MEFs] and the  
214 EpCAM-depleted cells from thymic lobes). \*\*: P = 0.0081, ns: P > 0.05 (Mood's median test with P-  
215 values adjusted with the false-discovery rate method; n = 5, 10 and 5 for ORFTOC, FTOC and MEFs +  
216 EpCAM-depleted cells, respectively, from 5 independent experiments). Graph represents individual  
217 datapoints with mean  $\pm$  SD. **(D)** Flow cytometry plots showing T cell development at D6 in controls  
218 (FTOCs [left] and MEFs + EpCAM-depleted cells reaggregates [right]). Gating strategy is indicated on  
219 the left. **(E)** Flow cytometry plot showing the absence of a CD45+ Lineage- population in control  
220 reaggregates containing only TECs cultured as organoids and MEFs. Gating strategy is indicated on  
221 the left. **(F)** Proportion of CD3 $\epsilon$ -positive, T cell receptor beta (TCR $\beta$ )-positive cells in ORFTOCs and  
222 FTOCs at day 6 and 13 (D13). \*\*\*: P = 0.0002, \*\*\*\*: P < 0.0001, ns: P > 0.05 (one-way ANOVA with  
223 Tukey's multiple comparisons test; n = 5, 5, 10 and 6 for D6 ORFTOCs, D13 ORFTOCs, D6 FTOCs  
224 and D13 FTOCs, respectively, from 5 independent experiments). Graph represents individual datapoints  
225 with mean  $\pm$  SD. **(G)** RNAScope image of D13 ORFTOC section highlighting Foxn1 expression (red)  
226 with nuclei counterstained using Spectral dapi (grey). Scale bar, 100 $\mu$ m. **(H)** Immunofluorescence  
227 images of D13 ORFTOC (left) and FTOC (right) sections showing KRT8 (blue) and MHCII staining  
228 (green). Scale bar, 100 $\mu$ m. **(I)** Immunofluorescence image of D13 ORFTOC section demonstrating the

229 presence of medullary cells (UEA1-reactivity [magenta]). Dapi counterstains nuclei (grey). Scale bar,  
230 100 $\mu$ m. (J) Zoomed immunofluorescence images of D13 ORFTOC section showing epithelial cells  
231 (EpCAM [blue]) and nuclei (dapi [grey]) (left), medullary cells (UEA1-reactivity [bright pink]) co-staining  
232 with epithelial cells (middle), and T cells (CD3 $\epsilon$  [amber]) in-between epithelial cells (right). Scale bars,  
233 100 $\mu$ m.

234


235 **ORFTOCs recapitulate in vivo-like TEC and T cell populations diversity and**  
236 **physiological T cell development**

237 To further characterize the cell types in ORFTOCs, we profiled them and FTOC controls  
238 through single cell RNA sequencing (Fig. 3A). This analysis revealed three main clusters  
239 corresponding to the epithelial, immune, and mesenchymal compartments of ORFTOCs (Fig  
240 3B). Unsupervised clustering identified 7 main clusters of epithelial cells (Fig. S3A), which we  
241 annotated according to in vivo datasets (Baran-Gale et al., 2020; Bautista et al., 2021;  
242 Bornstein et al., 2018; Gao et al., 2022; Nusser et al., 2022; Park et al., 2020): 'early cTECs',  
243 'cTECs', 'early mTECs', 'pre-Aire mTECs', 'Aire and Spink5 mTECs', 'tuft-like mTECs', and  
244 'adult bipotent progenitor-like' (Fig. S3B). For the immune cells, clusters covered the main T  
245 cell developmental stages defined in vivo (Cordes et al., 2022; Luis et al., 2016; Mingueneau  
246 et al., 2013; Park et al., 2020; Rothenberg, 2021; Zhou et al., 2019), spanning from progenitors  
247 to mature T cells (Fig. S3, C and D). Both ORFTOCs and FTOCs contributed to all  
248 subpopulations (Fig. 3, C and D), suggesting that ORFTOCs faithfully recapitulate the different  
249 cell types present in FTOC controls. The biggest differences were observed for clusters  
250 representing cTECs and early stages of T cell development: (i) more 'early cTECs' were  
251 present in FTOCs and (ii) more 'cTECs' and 'thymus-seeding progenitor (TSP) to DN early 1'  
252 and 'TSP to DN early 2' cells were present in ORFTOCs. A potential explanation for this is the  
253 difference in embryonic age between the epithelial cells used for organoids and FTOCs, as  
254 FTOCs were from E13.5 thymi to match T cell progenitors in ORFTOCs, while TECs in  
255 ORFTOCs were from E16.5 thymi.

256 To compare our in vitro populations with the in vivo thymus, we aligned our clusters to the  
257 mouse dataset of the reference atlas by Park et al. (Park et al., 2020) (Fig. 3, E and F). We  
258 found strong overlap in most epithelial cell types (Fig. 3E), with the cTECs aligning together  
259 and most in vitro mTEC clusters matching their in vivo counterparts. However, the 'adult  
260 bipotent progenitor-like' cluster was smaller in vivo compared to in vitro. Immune clusters from  
261 our dataset also matched clusters defined for in vivo populations (Fig. 3F), especially from the  
262 'DP blast'/'DP (P)' stage onwards and, most importantly, for the CD4 and CD8 stages (mature  
263 T cells).

264 Besides gene expression, we also studied in vitro TCR recombination dynamics through V(D)J  
265 sequencing, allowing us to map productive T cells bearing both TCR chains on the immune  
266 UMAP (Fig. 3G). The quantification of productive chains presenting all V(D)J regions showed  
267 that the recombination of the TCR $\beta$  (TRB) and - $\alpha$  (TRA) chains were mostly achieved prior to  
268 and at the DP stage, respectively (Fig. 3H), similarly to the Park dataset (Park et al., 2020). In  
269 addition, thymocytes underwent proliferation (marked by high *Cdk1* expression) in between  
270 the recombination stages (marked by high *Rag1* and *Rag2* expression) (Fig. 3I), which also  
271 aligns with in vivo data (Park et al., 2020; Rothenberg, 2021).

272 Taken together, these results show the transcriptional similarity of ORFTOCs to FTOCs and  
273 that ORFTOCs preserve in vivo-like TEC diversity and T cell development.



274 **Fig. 3. ORFTOCs recapitulate in vivo-like TEC and T cell populations diversity and physiological**  
275 **T cell development.** (A) Schematic of the conditions used for ORFTOC and FTOC single-cell RNA  
276 sequencing with hashtag antibodies (HTOs) and analyzed after 13 days in culture. (B) Uniform Manifold  
277 Approximation and Projection (UMAP) showing 3 main clusters corresponding to the main input  
278 populations (epithelial, immune and mesenchymal cells). (C) UMAP displaying ORFTOC and FTOC  
279 cells distribution in the different clusters. (D) Dot plot representing ORFTOC proportion for each cluster  
280 (dot) within the epithelial or immune main populations, as well as mean ORFTOC proportion and  
281 standard deviation. Dot colors are matching clusters colors (Fig. S3, A and C). No outliers within  
282 epithelial or immune compartments were identified by Grubbs test. (E - F) UMAPs showing the  
283 integration of the epithelial (E) and immune (F) clusters identified in this study (left) with the mouse  
284 dataset of the reference atlas by Park et al. (Park et al., 2020) (right). (G) UMAP of the immune cluster  
285 (grey), highlighting cells identified as productive and bearing both TCR chains (black). (H) Proportion of  
286 productive cells with rearranged TRB or both TRA and TRB chains for the main thymocyte  
287 developmental stages. (I) Dot plot representing the average expression level and the percentage of cells  
288 expressing the recombination enzymes *Rag1* and *Rag2* as well as the cyclin protein *Cdk1* during the  
289 recombination and proliferation stages of thymocyte development.


291 Epi: epithelial, Imm: immune, cTEC: cortical TECs, mTEC: medullary TECs, DN: double negative, ISP:  
292 intermediate single positive, Prolif: proliferative, commit: commitment, TSP: thymus-seeding  
293 progenitors, DP: double positive, (P): proliferative, (Q): quiescent, IELpB: intestinal intraepithelial  
294 lymphocytes precursor B, NKT: natural killer T, IELpA: intestinal intraepithelial lymphocytes precursor  
295 A, DC: dendritic cells, pDC: plasmacytoid dendritic cells, aDC: activated dendritic cells, Mac:  
296 macrophages Mono: monocytes, sel: selected.  
297

298 **ORFTOCs show thymus-like ability to attract new T cell progenitors and improved**  
299 **epithelial organization upon in vivo grafting**

300 The thymus continuously attracts bone marrow-derived hematopoietic precursors and commits  
301 them to the T cell lineage (Lai and Kondo, 2007; Lavaert et al., 2020). To test whether  
302 ORFTOCs retain this crucial capacity, we transplanted them under the kidney capsule of  
303 syngeneic CD45.1 recipient mice (Fig. 4A). After 5 weeks, all grafts developed into sizeable  
304 thymus-like tissues (4/4 ORFTOCs [Fig. 4B], 4/4 FTOC controls). Using flow cytometric  
305 analyses (Fig. S4A), we identified all major thymocyte populations (DN, DP, CD4, CD8) in  
306 ORFTOC grafts (Fig. 4C), and their proportions were comparable to FTOC control grafts and  
307 control thymi (Fig. 4D). This result demonstrated that normal  $\alpha\beta$ -TCR T cell lineage maturation  
308 was supported in ORFTOC grafts. A further detailed analysis (Fig. S4, B and C) detected  
309 thymocytes at the DN3 to DN4 transition at the time of ORFTOC graft retrieval, a stage  
310 attesting to successful  $\beta$ -selection (Rothenberg, 2021). In addition, DP thymocytes expressing  
311 CD69, which indicates positive selection-induced TCR signaling (Steier et al., 2023), were  
312 present (Fig. S3 B and D). Together, these results illustrate ORFTOC graft ability to  
313 continuously attract and select blood-borne T cell progenitors. Finally, the presence of  
314 CD45.1+ mature thymocytes (classified as M1 [CD24+ CD69+] and M2 [CD24+ CD69-],  
315 respectively [Fig. 4E and Fig. S4E]) and of regulatory T cells (Fig. 4F and Fig. S4F) showed  
316 ORFTOC graft capacity to generate mature CD4 and CD8 T cells, impose their post-selection  
317 maturation and select T cells with a regulatory phenotype.

318 Histological staining showed that ORFTOC grafts, similar to FTOC grafts, displayed the  
319 characteristic differences in cellular densities between cortical and medullary areas seen in the  
320 native thymus (Gordon and Manley, 2011) (Fig. S4G and Fig. 4G). Immunostaining confirmed  
321 the presence of medullary areas (positive for KRT5 and reactive to UEA1) containing Aire-  
322 positive cells (Fig. 4G). These medullary areas were larger, better organized and more mature  
323 compared to those observed after in vitro culture only (Fig. 2I), likely due to continuous seeding  
324 with new T cell progenitors and prolonged crosstalk with immune cells (Irla et al., 2010).

325 In conclusion, kidney capsule transplants showed that organoid-derived TECs in ORFTOCs  
326 have the (i) capacity to mature and reach an organization resembling the native thymus and  
327 (ii) long-term ability to attract T cell progenitors and mediate physiological T cell development.



328

330 **Fig. 4. ORFTOCs show thymus-like ability to attract new T cell progenitors and improved**  
331 **epithelial organization upon in vivo grafting. (A)** Schematic representing the experimental design for  
332 the grafting of ORFTOCs under the kidney capsule. **(B)** Widefield image of an ORFTOC graft retrieved  
333 after 5 weeks. Scale bar, 1mm. **(C)** Flow cytometry plot showing host thymocyte development in  
334 ORFTOC grafts. Gating strategy is indicated on the left. **(D)** Proportion of the major thymocyte  
335 subpopulations in ORFTOC grafts, in control FTOC grafts and thymi. ns: P > 0.05 (one-way ANOVA for  
336 each subpopulation between conditions; n = 3 grafts/mice for each condition). Bar graph represents  
337 mean ± SD and individual datapoints. **(E)** Flow cytometry plots showing two separate post-selection  
338 stages (M1 and M2) within the CD8+ and CD4+ SP populations in ORFTOC grafts. Gating strategy is  
339 indicated on the left. **(F)** Flow cytometry plot highlighting the presence of CD4 regulatory T cells (CD4reg)  
340 within the M2 population in ORFTOC grafts. Gating strategy is indicated on the left. **(G)**  
341 Immunofluorescence images of ORFTOC graft section. Left: medullary cells (KRT5 [amber]) are present  
342 in the less dense area (Dapi [grey]). Right: UEA1-reactive (azure) and Aire-positive cells (grey,  
343 highlighted with arrowhead) are also present in the medullary region. Scale bars, 100µm.

344

345 In this study, we showed that stromal cells of a lymphoid organ, namely epithelial cells of the  
346 thymus, can be cultured as organoids similarly to cells from other endoderm-derived organs.  
347 We established TEC-specific culture conditions, characterized the organoids, and  
348 demonstrated their superiority in maintaining TEC marker expression compared to  
349 conventional 2D cultures. Reaggregating TECs from organoid cultures with T cell progenitors  
350 proved their functionality and ability to mediate T cell development. TEC and T cell populations  
351 in reaggregates resembled the native cell types, and T cell maturation was recapitulated in a  
352 physiological manner. Finally, kidney capsule transplants demonstrated the long-term

353 capability of organoid reaggregates to attract new T cell progenitors and mediate their entire  
354 development.

355 Overall, this work addressed a long-standing challenge in the thymus field and presents the  
356 first method to culture TECs independently of other cell types in a way that maintains their  
357 thymopoietic ability. Although thymic epithelial organoids recapitulate many key organoid  
358 features such as cell population diversity and possibility to be expanded and passaged,  
359 maintaining their functionality in the long term remains challenging. This is probably linked to  
360 some niche factors missing in the current relatively minimal culture conditions, which over time  
361 either generally prevent functionality to be maintained or enrich for specific subsets that might  
362 lack functionality (Gao et al., 2022). Future work including single-cell transcriptomic analysis  
363 of the organoids will most likely help identify yet unexplored but necessary niche factors.

364 Thymic epithelial organoids nevertheless open up new opportunities to study T cell  
365 development in vitro in a physiological manner and gain new insights into TEC biology. As  
366 TECs undergo deterioration during aging and different medical conditions, the development of  
367 the current and future culture conditions might also pave the way for novel thymus regeneration  
368 strategies. Finally, to the best of our knowledge, the generation of bona fide organoids from  
369 the stromal compartment of a lymphoid organ is unprecedented.

370

371

372 **Materials and Methods**

373 **Mice**

374 For all in vitro experiments, C57BL/6J mice were purchased from Charles River France and  
375 maintained in the EPFL animal facility until use. For grafting experiments, Ly5.1 and C57BL/6J  
376 mice were bred and maintained in the mouse facility of the Department of Biomedicine at the  
377 University of Basel. For timed mating, noon of the day of the vaginal plug was considered as  
378 day 0.5 of embryonic development (E0.5). Mice were housed in individual cages at 23°C ± 1°C  
379 with a 12 h light/dark cycle, and supplied with food and water ad libitum. All animal work was  
380 conducted in accordance with Swiss national guidelines, reviewed and approved by the  
381 Cantonal Veterinary Offices of Vaud and of Basel-Stadt, license numbers VD3035.1, VD3823  
382 and BS2321.

383

384 **Isolation of thymic epithelial cells (TECs)**

385 E16.5 embryonic thymi were dissected and collected in Eppendorf tubes containing FACS  
386 buffer (PBS [Gibco Catalog No. 10010-015] + 2% fetal bovine serum [FBS] [Thermo Fisher  
387 Scientific, Catalog No. 26140079]). Lobes were rinsed with PBS and digested with 475 µl  
388 TrypLE (Gibco Catalog No. 12605-028) for 5 min at 37 °C under agitation (Eppendorf,  
389 ThermoMixer C). Lobes were pipetted to promote dissociation, 25 µl DNase (Sigma-Aldrich,  
390 Catalog No. 10104159001, from 1 mg/ml stock) was added and the tubes were incubated for  
391 another 5 min. Lobes were again pipetted to help dissociation, TrypLE was quenched with 1ml  
392 Adv. DMEM/F12 (Thermo Fisher Scientific, Catalog No. 12634028) containing 10 % FBS and  
393 the cell suspension was filtered through a 40 µm strainer. The cells were pelleted and  
394 resuspended in FACS buffer for staining with the following antibodies for 20 min at 4° C:  
395 Ter119-FITC (BioLegend, Catalog No. 116205, 1/100), EpCAM-PE (BioLegend, Catalog No.  
396 1198206, 1/80), PDGFR-α-APC (BioLegend, Catalog No. 135907, 1/40), PDGFR-β-ACP  
397 (BioLegend, Catalog No. 136007, 1/40), CD31-PE-Cy7 (BioLegend, Catalog No. 102524,  
398 1/160), MHCII-APC/Fire750 (BioLegend, Catalog No. 107651, 1/160), CD45-Pacific Blue  
399 (BioLegend, Catalog No. 103126, 1/200). Dapi (Tocris, Catalog No. 4748, 0.5 ug/ml) was used  
400 to exclude dead cells. After staining, the antibodies were washed and the cells resuspended  
401 in FACS buffer for sorting using an Aria Fusion (BD). The sorting strategy for isolating thymic  
402 epithelial cells is shown in Fig. S1 A. Sorted cells were collected in TEC medium (see below)  
403 containing 2 % FBS and 2.5 µM Thiazovivin (Stemgen, Catalog No. AMS.04-0017).

404

405

406 **Thymic epithelial organoid culture**

407 Sorted thymic epithelial cells were embedded in growth-factor-reduced Matrigel (Corning,  
408 Catalog No. 356231) ( $\sim 1.55 \times 10^4$  cells per 20 mL drop) and plated in 24-well plates (Corning,  
409 Catalog No. 353047, or Ibidi, Catalog No. 82426). After Matrigel polymerization, TEC medium  
410 was added. TEC medium consisted of organoid basal medium (Advanced DMEM/F-12  
411 supplemented with 1 $\times$  GlutaMAX [Thermo Fisher Scientific, Catalog No. 35050038], 10 mM  
412 HEPES [Thermo Fisher Scientific, Catalog No. 15630056], 100  $\mu$ g ml $^{-1}$  Penicillin–Streptomycin  
413 [Thermo Fisher Scientific, Catalog No. 15140122], 1 $\times$  B-27 supplement [Thermo Fisher  
414 Scientific, Catalog No. 17504001], 1 $\times$  N2 supplement [Thermo Fisher Scientific, Catalog No.  
415 17502001], 1 mM N-Acetylcysteine [Sigma-Aldrich, Catalog No. A9165]) plus 100 ng ml $^{-1}$   
416 FGF7 (Peprotech, Catalog No. 100-19). 2.5 $\mu$ M Thiazovivin was also added to the medium for  
417 the first two days. Medium was changed every second day. Organoids were cultured at 37°C  
418 with 5% CO $_2$ .

419

420 **Organoid proliferation assays**

421 Sorted thymic epithelial cells were embedded in 10  $\mu$ l Matrigel drops ( $\sim 7.5 \times 10^3$  cells/drop) in  
422 a 48-well plate (Corning, Catalog No. 353078). On the day of seeding (day 0), at day 1, 3, 5  
423 and 7, 220  $\mu$ M resazurin (Sigma-Aldrich, Catalog No. R7017) was added to organoid basal  
424 medium and incubated with the cells for 4 h at 37 °C. Afterwards, the resazurin-containing  
425 medium was collected and replaced by fresh TEC medium with or without FGF7. Organoid  
426 proliferation was estimated by measuring the reduction of resazurin to fluorescent resorufin in  
427 the medium using a Tecan Infinite F500 microplate reader (Tecan) with 560 nm excitation and  
428 590 nm emission filters. For analysis, data were normalized from minimum to maximum.

429

430 **Bulk transcriptome profiling**

431 Sorted thymic epithelial cells were culture as indicated above. As controls, sorted thymic  
432 epithelial cells from E16.5 embryos were either directly lysed in RLT buffer (QIAGEN, Catalog  
433 No. 74004) containing 40 mM DTT (ITW Reagents, Catalog No. A2948) or cultured in 2D on  
434 plates coated with 6  $\mu$ g/ml laminin (R&D Systems, Catalog No. 3446-005-01). Cultures were  
435 done in TEC medium. Organoids were collected in cold PBS to dissolve Matrigel and then  
436 lysed in RLT buffer with DTT. They were collected after 3 and 7 days. Cells cultured in 2D were  
437 directly collected in RLT buffer with DTT. They were collected once a confluent monolayer  
438 formed, after 3 days, as prolonged culture in these conditions lead to cell detachment and  
439 death. RNA was extracted using QIAGEN RNeasy Micro Kit (QIAGEN, Catalog No. 74004)  
440 according to manufacturer's instructions. Purified RNA was quality checked using a

441 TapeStation 4200 (Agilent), and 88 ng were used for QuantSeq 3' mRNA-Seq library  
442 construction according to manufacturer's instructions (Lexogen, Catalog No. 015.96). Libraries  
443 were quality checked using a Fragment Analyzer (Agilent) and were sequenced in a NextSeq  
444 500 (Illumina) using NextSeq v2.5 chemistry with Illumina protocol #15048776. Reads were  
445 aligned to the mouse genome (GRCm39) using star (version 2.7.0e). R (version 4.1.2) was  
446 used to perform differential expression analyses. Count values were imported and processed  
447 using edgeR (Robinson et al., 2010). Expression values were normalized using the trimmed  
448 mean of M values (TMM) method and lowly-expressed genes (< 1 counts per million) and  
449 genes present in less than three samples were filtered out. Differentially expressed genes were  
450 identified using linear models (Limma-Voom) (Smyth et al., 2018), and P-values were adjusted  
451 for multiple comparisons by applying the Benjamini-Hochberg correction method (Reiner et al.,  
452 2003). Voom expression values were used for hierarchical clustering using the function hclust  
453 (Murtagh, 1987) with default parameters, and for heatmap generation. Single sample gene set  
454 enrichment analysis (GSEA) (Subramanian et al., 2005) was used to score the E2F targets  
455 hallmark proliferation gene set (Howe et al., 2018; Liberzon et al., 2015) between samples.

456

#### 457 **Whole-mount immunofluorescence staining**

458 Organoid samples were fixed in 4% paraformaldehyde (Thermo Fisher Scientific, Catalog No.  
459 15434389) in PBS for 30 min at room temperature and subsequently washed with PBS.  
460 Samples were permeabilized in 0.2 % Triton X-100 (Sigma-Aldrich, Catalog No. T8787), 0.3  
461 M glycine (Invitrogen, Catalog No. 15527-013) in PBS for 30 min at room temperature and  
462 blocked in 10 % serum (goat [Thermo Fisher Scientific, Catalog No. 16210064] or donkey  
463 [Abcam, Catalog No. ab7475]), 0.01% Triton X100 and 0.3M glycine in PBS for 4h at room  
464 temperature. Samples were then incubated with primary antibodies overnight at 4 °C, washed  
465 with PBS, incubated with secondary antibodies overnight at 4 °C, and washed with PBS.  
466 Mounting was done with Fluoromount-G (SouthernBiotech, Catalog No. 0100-01). The  
467 following primary and secondary antibodies were used: MHCII-Biotin (BioLegend, Catalog No.  
468 107603, 1/200), UEA1 (Vector Laboratories Catalog No. B-1065, 1/500), Keratin 5 (BioLegend,  
469 Catalog No. 905501, 1/200), Keratin 8 (Abcam Catalog. No. ab53280, 1/200), Ki67 (BD  
470 Pharmingen, Catalog No. 550609, 1/200), EpCAM-APC (Invitrogen, Catalog No. 17-5791-82,  
471 1/200), Streptavidin Alexa 488 (Thermo Fisher Scientific, Catalog No. S-11223, 1/500),  
472 Streptavidin Alexa 647 (Thermo Fisher Scientific, Catalog No. S-21374, 1/500), Goat anti-Rat  
473 Alexa 647 (Thermo Fisher Scientific, Catalog No. A-21247, 1/500), Donkey anti-Mouse Alexa  
474 568 (Thermo Fisher Scientific, Catalog No. A-10037, 1/500), Donkey anti-Rabbit Alexa 488  
475 (Thermo Fisher Scientific, Catalog No. A-21206, 1/500), Donkey anti-Rabbit Alexa 568

476 (Thermo Fisher Scientific, Catalog No. A-11077, 1/500). Dapi (Tocris, Catalog No. 47481  
477 mg/ml) was used to stain nuclei.

478 **Reaggregate culture**

479 E13.5 embryonic thymi were dissected and collected in Eppendorf tubes containing FACS  
480 buffer. Lobes were rinsed with PBS and digested with 475  $\mu$ l TrypLE and 25  $\mu$ l DNase (from 1  
481 mg/ml stock) for 5 min under agitation. Lobes were pipetted to help dissociation and TrypLE  
482 was quenched with 1ml Adv. DMEM/F12 containing 10 % FBS. The cells were pelleted and  
483 resuspended in FACS buffer for immunomagnetic cell separation with EpCAM-conjugated  
484 beads (Miltenyi Biotec, Catalog No. 130-105-958, 1/4). After 20 min incubation at 4°C, the  
485 unbound complexes were washed and the cells processed through magnetic columns (Miltenyi  
486 Biotec, Catalog No. 130-042-401) following manufacturer instruction. The EpCAM-depleted  
487 fraction was collected and used to prepare reaggregates with dissociated thymic epithelial  
488 organoids and mouse embryonic fibroblasts (MEFs).

489 Thymic epithelial organoids at day 7 of culture were collected in cold Advanced DMEM/F-12  
490 supplemented with 1 $\times$  GlutaMAX, 10 mM HEPES and 100  $\mu$ g ml $^{-1}$  Penicillin–Streptomycin.  
491 Organoids were pelleted and digested with 950  $\mu$ l TrypLE and 50  $\mu$ l DNase (from 1 mg/ml) for  
492 5min at 37 °C. Organoids were pipetted to improve dissociation. In case digestion was  
493 insufficient, organoids were further digested for 5 min with Trypsin + 0.25% EDTA (Gibco,  
494 Catalog No. 25200-072) at 37 °C and pipetted until the obtention of a single cell suspension.  
495 Dissociation was quenched with Adv. DMEM/F12 containing 10 % FBS and the cells pelleted.  
496 Wild-type MEFs were a kind gift from the Blackburn laboratory. MEFs were cultured in  
497 Advanced DMEM/F-12 supplemented with 1 $\times$  GlutaMAX, 1x Non-Essential Amino Acids  
498 (Gibco, Catalog No. 11140035), 100  $\mu$ g ml $^{-1}$  Penicillin–Streptomycin and 10 % FBS on gelatin-  
499 coated dishes (0.1% gelatin in H<sub>2</sub>O) (Sigma-Aldrich, Catalog No. G1890). MEFs were  
500 harvested using Trypsin EDTA 0.25% for 2 min at 37 °C. Dissociation was quenched with Adv.  
501 DMEM/F12 containing 10 % FBS and the cells pelleted.

502 For reaggregates using adult double negative 1 (DN1) thymocytes as input population, adult  
503 thymi were dissected from 4 weeks old female C57BL/6J mice. Thymi were cut in small pieces  
504 with a scalpel to liberate thymocytes, which were filtered to a single cell suspension with a 40  
505  $\mu$ m strainer. Cells were incubated with APC anti-mouse CD8a Antibody (BioLegend, Catalog  
506 No. 100711, 1/50) for 20 min at 4°C in FACS buffer and washed. Cells were then incubated  
507 with anti-APC magnetic beads (Miltenyi Biotec, Catalog No. 130-090-855, 1/4) for 20 min at  
508 4°C. The unbound beads were washed away and the cells processed through magnetic  
509 columns following manufacturer instruction. The APC depleted fraction was collected and used  
510 for staining with the following antibodies: Ter119-FITC (BioLegend, Catalog No. 116205,

511 1/800), Cd45R-FITC (BioLegend, Catalog No. 103205, 1/800), CD11b-FITC (Thermo Fisher  
512 Scientific, Catalog No. 11-0112-82, 1/800), Ly-6G-FITC (BioLegend, Catalog No. 108405,  
513 1/800), Cd11C-FITC (BioLegend, Catalog No. 117306, 1/800), NK-1.1-FITC (BioLegend,  
514 Catalog No. 108705, 1/800), CD3-FITC (BioLegend, Catalog No. 100306), CD4-FITC  
515 (BioLegend, Catalog No. 100510), CD45-Pacific Blue (BioLegend, Catalog No. 103126, 1/200)  
516 or CD45-AF700 (BioLegend, Catalog No. 103127, 1/160), CD44-PE (BioLegend, Catalog No.  
517 103008, 1/160), CD25-BV711 (BioLegend, Catalog No. 102049, 1/160) and Dapi (Tocris,  
518 Catalog No. 4748, 0.5 ug/ml). After staining, the antibodies were washed and the cells  
519 resuspended in FACS buffer for sorting using an Aria Fusion (BD). The sorting strategy for  
520 isolating DN1 thymocytes was gating on cells, single cells, live cells, CD45+ cells, CD44+  
521 CD25- cells. DN1 thymocytes were collected in ORFTOC medium (see below).

522 Organoids reaggregate fetal thymic organ culture (ORFTOCs) were prepared as previously  
523 described (Sheridan et al., 2009). Briefly, the cell suspension for each ORFTOC typically  
524 contained  $10^5$  EpCAM-depleted cells,  $10^5$  thymic epithelial organoid cells, and  $10^5$  MEFs (or  
525  $10^5$  thymic epithelial organoid cells,  $4 \times 10^4$  DN1 thymocytes and  $10^5$  MEFs). These cells were  
526 transferred to an Eppendorf tube and pelleted. The pellet was resuspended in 60  $\mu$ l of the  
527 medium used for culture, and transferred to a tip sealed with parafilm inside a 15 ml Falcon  
528 tube. Cells were pelleted inside the tip for 5 min at 470 rcf. The pellet was then gently extruded  
529 on top of a filter membrane (Merck, Catalog No. ATTP01300) floating on culture medium in  
530 24well plate. ORFTOC culture medium consisted of advanced DMEM/F-12 supplemented with  
531 1x GlutaMAX, 1x Non-Essential Amino Acids, 100  $\mu$ g ml<sup>-1</sup> Penicillin–Streptomycin, 2 % FBS  
532 and 100 ng/ml FGF7. 2.5 $\mu$ M Thiazovivin was added for the first two days of culture and half of  
533 the medium volume was changed every second day.

534 Controls where one of the cell population is absent were made the same way. For FTOC  
535 controls, E13.5 dissected lobes were directly placed on top of a filter membrane and also  
536 cultured in ORFTOC medium.

537 All cultures were done at 37°C with 5% CO<sub>2</sub>.

538

### 539 **Flow cytometry analysis of ORFTOCs and FTOCs**

540 After 6 and 13 days in culture, ORFTOCs, FTOCs, reaggregates with DN1 thymocytes and  
541 controls reaggregates were gently detached from the filter membrane by pipetting and  
542 transferred to Eppendorf tubes, together with the culture medium to collect recently emigrated  
543 T cells. Samples were pelleted, rinsed with PBS and digested with 200  $\mu$ l TrypLE for 10 min at  
544 37° C with agitation on an Eppendorf shaker (800 rpm). Dissociation was quenched with 1ml  
545 Adv. DMEM/F12 containing 10 % FBS and the cells pelleted. Cells were resuspended in FACS

546 buffer for staining. The cells were incubated for 20 min with the following antibodies: Ter119-  
547 FITC (BioLegend, Catalog No. 116205, 1/800), Cd45R-FITC (BioLegend, Catalog No. 103205,  
548 1/800), CD11b-FITC (Thermo Fisher Scientific, Catalog No. 11-0112-82, 1/800), Ly-6G-FITC  
549 (BioLegend, Catalog No. 108405, 1/800), Cd11C-FITC (BioLegend, Catalog No. 117306,  
550 1/800), NK-1.1-FITC (BioLegend, Catalog No. 108705, 1/800) together referred as Lineage,  
551 CD44-PE (BioLegend, Catalog No. 103008, 1/160), CD69-APC (BioLegend, Catalog No.  
552 104513, 1/160), CD4-BV605 (BioLegend, Catalog No. 100548, 1/40), CD3-PerCP/Cy5.5  
553 (BioLegend, Catalog No. 100327, 1/160), CD8-PE/Cy7 (BioLegend, Catalog No. 100722,  
554 1/160), CD25-BV711 (BioLegend, Catalog No. 102049, 1/160), CD45-AF700 (BioLegend,  
555 Catalog No. 103127, 1/160), TCR $\beta$ -BV421 (BioLegend, Catalog No. 109230, 1/80) and Dapi  
556 (Tocris, Catalog No. 4748, 0.5 ug/ml). After staining, the antibodies were washed and the cells  
557 resuspended in FACS buffer for analyzing using a LSR Fortessa Cytometer (BD). The gating  
558 strategy for analysis is shown in Fig. S2 B. Beads (UltraComp, Thermo Fisher Scientific  
559 Catalog No. 01-3333-42) were used for single color staining for compensation. Gates were  
560 based on T cells extracted from a young adult. Flow cytometry data were analyzed using  
561 FlowJo (BD, version 10.9.0).

562

### 563 **Single-cell transcriptome profiling**

564 After 13 days in culture, ORFTOC and FTOC samples were collected and dissociated as  
565 described for flow cytometry analysis. After dissociation, two ORFTOC samples and two FTOC  
566 samples were pooled, respectively. For each pool, 500 000 cells were incubated with 1ul  
567 TotalSeq Antibody (HTO) (BioLegend, Catalog No. 155863 and 155861) in 50  $\mu$ l FACS buffer  
568 for 30 min on ice. Antibodies were washed two times with FACS buffer and the single cell  
569 suspensions filtered through a 40  $\mu$ m strainer. After cell count, samples were mixed in a 1:1  
570 ratio and processed using Chromium Next GEM Single Cell 5' Reagent Kits v2 (Dual Index)  
571 with Feature Barcode technology for Cell Surface Protein & Immune Receptor Mapping  
572 reagents (10X Genomics, Catalog No. PN-1000265, PN-1000256, PN-1000190, PN-1000287,  
573 PN-1000215 and PN-100025) following manufacturer's instruction. Single Cell Mouse TCR  
574 amplification Kit (10X Genomics Catalog No. 1000254) was used to prepare TCR libraries.  
575 Sequencing was done using NovaSeq v1.5 STD (Illumina protocol #1000000106351 v03) for  
576 around 100,000 reads per cell. The reads were aligned using Cell Ranger v6.1.2 to the mouse  
577 genome (mm10). Raw count matrices were imported into R and analyzed using Seurat v4.2.0  
578 (Hao et al., 2021). HTO with less than 100 features and less than 1 count were discarded.  
579 Cells with less than 600 features, less than 0.4 or more than 10 percent mitochondrial genes  
580 were discarded. Demultiplexing was performed using HTODemux with standard parameters.  
581 Doublets were removed using recoverDoublets from scDblFinder package (Germain et al.,

582 2022) and based on doublets identified from HTOs. Data were normalized using SCTtransform  
583 and with cell cycle score as variable to regress. The three clusters representing the main cell  
584 types were obtained using PCA and UMAP with 18 dimensions and a resolution of 0.005. Each  
585 cell type was then subset and thresholded based on *EpCAM*, *Ptprc* and *Pdgfra* expression.  
586 Epithelial clusters were identified using 18 dimensions and a resolution of 0.4, leading to 7  
587 clusters that were named based on markers from previous datasets (Baran-Gale et al., 2020;  
588 Bautista et al., 2021; Bornstein et al., 2018; Gao et al., 2022; Kernfeld et al., 2018; Park et al.,  
589 2020). Immune clusters were identified using 18 dimensions and a resolution of 3. Immune  
590 clusters were further merged to obtain 14 clusters representing main T cell developmental  
591 stages based on markers from previous datasets (Cordes et al., 2022; Mingueneau et al.,  
592 2013; Park et al., 2020; Rothenberg, 2021). The number of cells per clusters in both FTOC  
593 and RFTOC samples were calculated to show HTO repartition between both samples. TCR  
594 analysis was conducted using scRepertoire (Borcherding et al., 2020). Filtered contig output  
595 from Cell Ranger was used as input and added to immune cells metadata. Productive cells  
596 with both TRA and TRB chains were plotted on the UMAP, and percentage of productive cell  
597 (either at least TRB chain with no NA and no double chain, or both TRA and TRB chains with  
598 no NA and double chain accepted only for TRA) per cluster calculated. The mouse samples  
599 from the dataset from Park et al. (Park et al., 2020) were used for alignment. H5ad files were  
600 converted to Seurat object, TECs were subset from the stromal dataset and 4 weeks-old T  
601 cells from the mouse total dataset. Alignment was performed using SCTtransform and  
602 canonical correlation analysis (CCA) with the Park dataset labeled as reference and otherwise  
603 default parameters.

604

## 605 **Kidney capsule grafting and analysis**

606 ORFTOCs were grafted in CD45.1 host mice and FTOC controls in CD45.2 host mice. Mice  
607 were treated with the analgesic Carprofen (10 mg/kg in drinking water) 12-24 h prior to  
608 transplantation. Mice were anesthetized with Ketalar/Rompun (100 mg/kg Ketamin and 20  
609 mg/kg Xylazin, intraperitoneal). Lacrinorm eye gel (Bausch & Lomb) was administered to avoid  
610 dehydration of the cornea during the procedure. Anesthetized mice were shaved laterally and  
611 disinfected using Betadine. The surgery was performed on a heating pad in order to minimize  
612 body temperature drop. A small incision of approximately 1 cm was done first on the skin and  
613 then in the peritoneum. By pulling at the posterior fat of the kidney with forceps, the kidney was  
614 exposed outside of the peritoneum and kept wet with PBS. Under the microscope, an incision  
615 and a channel were done with watchmaker-forceps on the kidney capsule's membrane and  
616 one ORFTOC or FTOC was placed under the membrane. After positioning the kidney back  
617 into the peritoneum, the wound was closed with two stitches (resorbable suture material 5/0;

618 Polyactin 910; RB-1 plus; Johnson&Johnson). The skin opening was closed with staples,  
619 which were removed 7-10 days later. An analgesic (Temgesic, Buprenorphine 0.1 mg/kg,  
620 subcutaneous) was administered at the end of the procedure followed by continuous treatment  
621 of transplanted mice by Carprofen (10 mg/kg in drinking water) for 3 days. After the transplants,  
622 mice were monitored daily and weighed every second day to confirm their wellbeing. Grafts  
623 were analyzed 5 weeks after transplantation.

624 At the time of analysis, mice were sacrificed with CO<sub>2</sub> and kidneys retrieved. Grafts were  
625 separated from the kidney under the microscope. To collect T cells, grafts were mechanically  
626 dissociated by pipetting in FACS buffer. Single cell suspensions were then stained with Zombie  
627 NIR (BioLegend, Catalog No. 423105, 1/1000) for 30 min at 4° C. Samples were then washed  
628 with FACS buffer and incubated with the following Lineage antibodies for 30 min at 4°C: CD11b  
629 Biotin (BioLegend, Catalog No. 101204, 1/1000), CD11c Biotin (BioLegend, Catalog No.  
630 117304, 1/1000), CD19 Biotin (BioLegend, Catalog No. 101504, 1/1000), DX5 Biotin  
631 (BioLegend, Catalog No. 108904, 1/1000), MHCII Biotin (BioLegend, Catalog No. 116404,  
632 1/1000), GR1 Biotin (BioLegend, Catalog No. 108404, 1/1000), F4/80 Biotin (BioLegend,  
633 Catalog No. 123100, 1/1000), Ter119 Biotin (BioLegend, Catalog No. 116204, 1/1000) and  
634 NK-1.1 Biotin (BioLegend, Catalog No. 108704, 1/1000). After washes, samples were  
635 incubated with the following antibodies for 30 min at 4°C : CD45.1-PerCP-Cy5.5 (BioLegend,  
636 Catalog No. 110728, 1/500), CD45.2-BV650 (BioLegend, Catalog No. 109836, 1/200), CD4-  
637 BUV563 (Thermo Fisher Scientific, Catalog No. 365-0042-82, 1/1000), CD8-BUV615 (Thermo  
638 Fisher Scientific, Catalog No. 366-0081-82, 1/500), TCR $\alpha$ -PE-Dazzle594 (BioLegend,  
639 Catalog No. 109220, 1/500), TCR $\gamma$ -PE (BioLegend, Catalog No. 118108, 1/500), CD69-FITC  
640 (BioLegend, Catalog No. 104506, 1/500), CD24-APC (BioLegend, Catalog No. 101814,  
641 1/1000), CD44-BV785 (BioLegend, Catalog No. 103059, 1/500), Ckit-BUV737 (Thermo Fisher  
642 Scientific, Catalog No. 367-1171-82, 1/200), CD71-PE-Cy7 (BioLegend, Catalog No. 113812,  
643 1/200), Sca1-BUV395 (Thermo Fisher Scientific, Catalog No. 363-5981-82, 1/500), CD25-  
644 BV605 (BioLegend, Catalog No. 102036, 1/500), CD5-APC-eF780 (Thermo Fischer Scientific,  
645 Catalog No. 47-0015-82, 1/500) and Streptavidin-BV510 (Biolegend, Catalog No. 405234,  
646 1/500). After final washes, samples were resuspended in FACS buffer and analyzed on an  
647 Aurora flow cytometer (Cytek Biosciences). Flow cytometry data were then analyzed using  
648 FlowJo (version 10.9.0).

649

## 650 **Sectioning, immunofluorescence staining and RNA scope on sections**

651 Organoids, ORFTOCs, FTOCs and grafts were fixed in 4% paraformaldehyde in PBS for 30  
652 min at room temperature (organoids) to overnight at 4 °C (ORFTOCs, FTOCs, grafts). Samples  
653 were then washed with PBS and either processed for cryosectioning or for paraffin embedding.

654 For cryosectioning, samples were incubated in 30% (W/V) sucrose (Sigma-Aldrich, Catalog  
655 No. S1888) in PBS until the sample sank. Subsequently, samples were incubated for 12 h in  
656 a mixture of Cryomatrix (Epredia, Catalog No. 6769006) and 30% sucrose (Sigma-Aldrich,  
657 Catalog No. 84097) (mixing ratio 50/50), followed by a 12 h incubation in pure Cryomatrix. The  
658 samples were then embedded in a tissue mold, frozen on dry ice or in isopentane cooled by  
659 surrounding liquid nitrogen. 10  $\mu$ m-thick sections were cut at -20°C using a CM3050S cryostat  
660 (Leica).

661 For paraffin embedding, organoid, ORFTOC and FTOC samples were  
662 embedded in HistoGel (Thermo Fisher Scientific, Catalog No. HG-4000-012) before being  
663 placed into histology cassettes. Cassettes were then processed with a Tissue-Tek VIP 6 AI  
664 Vacuum Infiltration Processor (Sakura) and embedded in paraffin. 4  $\mu$ m paraffin sections were  
665 obtained with a Leica RM2265 microtome. Slides were processed through de-waxing and  
666 antigen retrieval in citrate buffer at pH 6.0 using a heat-induced epitope retrieval PT module  
667 (Thermo Fisher Scientific) before proceeding with immunostaining.  
668 Sections were then blocked and permeabilized for 30 min in 1% BSA (Thermo Fischer  
669 Scientific, Catalog No. 15260-037), 0.2% Triton X100 in PBS and blocked for 30 min in 10%  
670 goat or donkey serum in PBS at room temperature. Primary antibodies were incubated O/N at  
671 4 °C in PBS, 1.5% donkey or goat serum. On the following day, slices were washed twice in  
672 1% BSA, 0.2% Triton X-100 in PBS and incubated with secondary antibodies at room  
673 temperature for 45 min. Finally, slices were washed twice in 0.2% Triton X-100 in PBS and  
674 mounted with Fluoromount-G. The following primary and secondary antibodies were used:  
675 UEA1 (Vector Laboratories, Catalog No. B-1065, 1/500), Keratin 5 (BioLegend, Catalog No.  
676 905501, 1/200), Keratin 8 (Abcam, Catalog. No. ab53280, 1/200), CD3 $\epsilon$  (Thermo Fisher  
677 Scientific, Catalog No. MA5-14524, 1/200), MHCII-Biotin (BioLegend, Catalog No. 107603,  
678 1/200) EpCAM-PE (BioLegend, Catalog No. 118206, 1/200), Aire (Thermo Fisher Scientific,  
679 Catalog No. 14-5934-82, 1/50), Streptavidin Alexa 488 (Thermo Fisher Scientific, Catalog No.  
680 S-11223, 1/500), Goat anti-Rat Alexa 568 (Thermo Fisher Scientific, Catalog No. A-11077,  
681 1/500), and Donkey anti-Rabbit Alexa 647 (Thermo Fisher Scientific, Catalog No. A-31573,  
682 1/500). Nuclei were again stained with Dapi (Tocris, Catalog No. 4748, 1 ug/ml).  
683 RNAscope Multiplex Fluorescent V2 assay (Bio-Techne, catalog no. 323110) was performed  
684 according to the manufacturer's protocol. Paraffin sections were hybridized with the probes  
685 Mm-Foxn1 (Bio-Techne, catalog no. 482021). Mm-3Plex probes (Bio-Techne, catalog no.  
686 320881) and 3Plex Dapb probes (Bio-Techne, catalog no. 320871) were used as positive and  
687 negative controls, respectively. Probes were incubated at 40°C for 2 hours, and the different  
688 channels were revealed with TSA Opal570 (Akoya Biosciences, catalog no. FP1488001KT).  
689 Tissues were counterstained with Dapi and mounted with ProLong Gold Antifade Mountant

690 (Thermo Fisher Scientific, P36930). Hematoxylin and eosin staining was performed using a  
691 Ventana Discovery Ultra automated slide preparation system (Roche).

692

### 693 **Microscopy and image analysis**

694 Live brightfield imaging was performed using a Nikon Eclipse Ti2 inverted microscope with  
695 4 $\times$ /0.13 NA, 10 $\times$ /0.30 NA, and 40 $\times$ /0.3 NA air objectives and a DS-Qi2 camera (Nikon  
696 Corporation). Time lapse was imaged with a Nikon Eclipse Ti inverted microscope system  
697 equipped with a 20 $\times$ /0.45 NA air objective and a DS-Qi2 camera (Nikon Corporation). Both  
698 microscopes were controlled using the NIS-Elements AR software (Nikon Corporation).  
699 Extended depth of field (EDF) of brightfield images was calculated using a built-in NIS-  
700 Elements function. Fluorescent confocal imaging of fixed whole-mount and sections was done  
701 on a Leica SP8 microscope system, equipped with a 20 $\times$ /0.75 NA air and a 40 $\times$ /1.25 glycerol  
702 objectives, 405 nm, 488 nm, 552nm and 638 nm solid state lasers, DAPI, FITC, RHOD and Y5  
703 filter cubes, a DFC 7000 GT (Black/White) camera and a CCD grayscale chip. Sections were  
704 also imaged on a Leica DM5500 upright microscope equipped with a 20 $\times$ /0.7 NA air and a  
705 40 $\times$ /1 NA oil objectives, a DFC 3000 (Black/White) or a DMC 2900 (Color) cameras and a CCD  
706 grayscale or a CMOS color chip, respectively. Both Leica microscopes were controlled by the  
707 Leica LAS-X software (Leica microsystems). For image processing, only standard contrast-  
708 and intensity-level adjustments were performed, using Fiji/ImageJ (NIH) (version 2.1.0/1.53c).

709

### 710 **Statistics**

711 The number of replicates ( $n$ ), the number of independent experiments or animals, the type of  
712 statistical tests performed, and the statistical significance are indicated for each graph in the  
713 figure legend. Statistical significance was analyzed using one- or two-way ANOVA, Brown-  
714 Forsythe ANOVA in case of heteroscedasticity or Mood's median test in the absence of normal  
715 distribution. For multiple comparisons, one-way ANOVA were followed by Tukey's test, Brown-  
716 Forsythe ANOVA by Dunnet's T3 test, and Mood's test results adjusted for false-discovery  
717 rate. Data normality and equality of variances were previously tested with Shapiro-Wilk and  
718 Brown-Forsythe test, respectively. Grubbs test was used to determine the presence of outliers  
719 across scRNASeq subpopulations. In all cases, values were considered significant when  $P \leq$   
720 0.05. Graphs show individual datapoints with mean  $\pm$  standard deviation (SD). Tests were  
721 performed using Prism (GraphPad, version 9.4.0), except Grubbs test which was performed  
722 using GraphPad website (<https://www.graphpad.com/quickcalcs/grubbs1/>) and Mood's test  
723 which was performed using the package rcompanion (Mangiafico, 2016) in R (version 4.1.2).  
724 Graphs were made using Prism.

725 **Acknowledgements**

726 We thank all present and past LSCB members and in particular Antonius Chrisnandy, Bilge  
727 Sen Elci and Moritz Hofer for discussions and sharing materials. We thank Julia Prébandier  
728 for administrative assistance and Katrin Hafen for technical expertise. We acknowledge  
729 support and work from the Flow Cytometry, Centre de Phénogénomique, Gene Expression,  
730 Histology and Biolimaging and Optics EPFL core facilities. We thank all collaborators from the  
731 Syn-Thy project, in particular Graham Anderson, Viktorja Major, Joanna Sweetman and Tim  
732 Henderson and for their feedback.

733

734 **Author contributions**

735 TH conceived the study, designed and carried experiments, analyzed results, prepared  
736 artwork, and wrote the manuscript. LFLM helped with experimental design, experimental and  
737 analysis work and provided feedback on the manuscript. TB performed grafting experiment  
738 and analysis and provided feedback. LT and JJL helped with experiments. PR taught methods,  
739 provided feedback and shared reagents. CCB and GH provided feedback on the work and  
740 edited the manuscript. MPL conceived the work, designed experiments, and carried out the  
741 final editing of the manuscript.

742

743 **Competing interests**

744 The authors declare no competing interests.

745

746 **Funding**

747 This work was funded by the Wellcome Trust Wellcome Collaborative Award (SynThy,  
748 211944/Z/18/Z) and EPFL.

749

750 **Data availability**

751 Sequencing data reported in this paper have been deposited in the Gene Expression Omnibus  
752 (GEO) public repository under the accession number GSE240698. The SubSeries  
753 GSE240696 and GSE240697 corresponds to bulk and single-cell RNA-seq, respectively. Code  
754 used for analysis is available upon request and will be published on Github.

755

756 **References**

757 **Alawam, A. S., Anderson, G. and Lucas, B.** (2020). Generation and Regeneration of Thymic  
758 Epithelial Cells. *Front. Immunol.* **11**, 1–15.

759 **Anderson, G. and Jenkinson, E. J.** (1998). Use of explant technology in the study of in vitro  
760 immune responses. *J. Immunol. Methods* **216**, 155–163.

761 **Anderson, G., Jenkinson, E. J., Moore, N. C. and Owen, J. J. T.** (1993). MHC class II-  
762 positive epithelium and mesenchyme cells are both required for T cell development in the  
763 thymus. *Nature* **362**, 70–73.

764 **Anderson, K. L., Moore, N. C., McLoughlin, D. E. J., Jenkinson, E. J. and Owen, J. J. T.**  
765 (1998). Studies on thymic epithelial cells in vitro. *Dev. Comp. Immunol.* **22**, 367–377.

766 **Asnaghi, M. A., Barthlott, T., Gullotta, F., Strusi, V., Amovilli, A., Hafen, K., Srivastava,  
767 G., Oertle, P., Toni, R., Wendt, D., et al.** (2021). Thymus Extracellular Matrix-Derived  
768 Scaffolds Support Graft-Resident Thymopoiesis and Long-Term In Vitro Culture of Adult  
769 Thymic Epithelial Cells. *Adv. Funct. Mater.* **31**, 2010747.

770 **Baran-Gale, J., Morgan, M. D., Maio, S., Dhalla, F., Calvo-Asensio, I., Deadman, M. E.,  
771 Handel, A. E., Maynard, A., Chen, S., Green, F., et al.** (2020). Ageing compromises  
772 mouse thymus function and remodels epithelial cell differentiation. *Elife* **9**, 1–71.

773 **Bautista, J. L., Cramer, N. T., Miller, C. N., Chavez, J., Berrios, D. I., Byrnes, L. E.,  
774 Germino, J., Ntranos, V., Sneddon, J. B., Burt, T. D., et al.** (2021). Single-cell  
775 transcriptional profiling of human thymic stroma uncovers novel cellular heterogeneity in  
776 the thymic medulla. *Nat. Commun.*

777 **Boehm, T. and Swann, J. B.** (2013). Thymus involution and regeneration: Two sides of the  
778 same coin? *Nat. Rev. Immunol.* **13**, 831–838.

779 **Bonfanti, P., Claudinot, S., Amici, A. W., Farley, A., Blackburn, C. C. and Barrandon, Y.**  
780 (2010). Microenvironmental reprogramming of thymic epithelial cells to skin multipotent  
781 stem cells. *Nature* **466**, 978–982.

782 **Borcherding, N., Bormann, N. L. and Kraus, G.** (2020). scRepertoire: An R-based toolkit for  
783 single-cell immune receptor analysis. *F1000Research* **9**, 1–17.

784 **Bornstein, C., Nevo, S., Giladi, A., Kadouri, N., Pouzolles, M., Gerbe, F., David, E.,  
785 Machado, A., Chuprin, A., Tóth, B., et al.** (2018). Single-cell mapping of the thymic  
786 stroma identifies IL-25-producing tuft epithelial cells. *Nature* **559**, 622–626.

787 **Bourgine, P. E., Klein, T., Paczulla, A. M., Shimizu, T., Kunz, L., Kokkaliaris, K. D., Coutu,  
788 D. L., Lengerke, C., Skoda, R., Schroeder, T., et al.** (2018). In vitro biomimetic  
789 engineering of a human hematopoietic niche with functional properties. *Proc. Natl. Acad.  
790 Sci. U. S. A.* **115**, E5688–E5695.

791 **Bredenkamp, N., Ulyanchenko, S., O'Neill, K. E., Manley, N. R., Vaidya, H. J. and  
792 Blackburn, C. C.** (2014). An organized and functional thymus generated from FOXN1-  
793 reprogrammed fibroblasts. *Nat. Cell Biol.* **16**, 902–908.

794 **Campinoti, S., Gjinovci, A., Ragazzini, R., Zanieri, L., Ariza-McNaughton, L., Catucci, M.,  
795 Boeing, S., Park, J. E., Hutchinson, J. C., Muñoz-Ruiz, M., et al.** (2020). Reconstitution  
796 of a functional human thymus by postnatal stromal progenitor cells and natural whole-  
797 organ scaffolds. *Nat. Commun.* **11**, 6372.

798 **Chaudhry, M. S., Velardi, E., Dudakov, J. A. and van den Brink, M. R. M.** (2016). Thymus:  
799 The next (re)generation. *Immunol. Rev.* **271**, 56–71.

800 **Cordes, M., Canté-Barrett, K., van den Akker, E. B., Moretti, F. A., Kielbasa, S. M.,  
801 Vloemans, S. A., Garcia-Perez, L., Teodosio, C., van Dongen, J. J. M., Pike-Overzet,  
802 K., et al.** (2022). Single-cell immune profiling reveals thymus-seeding populations, T cell  
803 commitment, and multilineage development in the human thymus. *Sci. Immunol.* **7**,

804 **Fan, Y., Tajima, A., Goh, S. K., Geng, X., Gualtierotti, G., Grupillo, M., Coppola, A.,  
805 Bertera, S., Rudert, W. A., Banerjee, I., et al.** (2015). Bioengineering Thymus Organoids  
806 to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts.  
807 *Mol. Ther.* **23**, 1262–1277.

808 **Gao, H., Cao, M., Deng, K., Yang, Y., Song, J., Ni, M., Xie, C., Fan, W., Ou, C., Huang, D.,  
809 et al.** (2022). The Lineage Differentiation and Dynamic Heterogeneity of Thymic Epithelial

810 Cells During Thymus Organogenesis. *Front. Immunol.* **13**, 1–24.

811 **Germain, P. L., Robinson, M. D., Lun, A., Garcia Meixide, C. and Macnair, W.** (2022).  
812 Doublet identification in single-cell sequencing data using scDblFinder. *F1000Research*  
813 **10**, 1–26.

814 **Giger, S., Hofer, M., Miljkovic-Licina, M., Hoehnel, S., Brandenberg, N., Guiet, R., Ehrbar,**  
815 **M., Kleiner, E., Gegenschatz-Schmid, K., Matthes, T., et al.** (2022). Microarrayed  
816 human bone marrow organoids for modeling blood stem cell dynamics. *APL Bioeng.* **6**,

817 **Gordon, J. and Manley, N. R.** (2011). Mechanisms of thymus organogenesis and  
818 morphogenesis. *Development* **138**, 3865–3878.

819 **Goyal, G., Prabhala, P., Mahajan, G., Bausk, B., Gilboa, T., Xie, L., Zhai, Y., Lazarovits,**  
820 **R., Mansour, A., Kim, M. S., et al.** (2022). Ectopic Lymphoid Follicle Formation and  
821 Human Seasonal Influenza Vaccination Responses Recapitulated in an Organ-on-a-  
822 Chip. *Adv. Sci.* **9**, 1–15.

823 **Hao, Y., Hao, S., Andersen-nissen, E., Gottardo, R., Smibert, P., Hao, Y., Hao, S.,**  
824 **Andersen-nissen, E., Iii, W. M. M., Zheng, S., et al.** (2021). Resource Integrated  
825 analysis of multimodal single-cell data II Integrated analysis of multimodal single-cell  
826 data. *Cell* **184**, 3573–3587.e29.

827 **Howe, D. G., Blake, J. A., Bradford, Y. M., Bult, C. J., Calvi, B. R., Engel, S. R., Kadin, J.**  
828 **A., Kaufman, T. C., Kishore, R., Laulederkind, S. J. F., et al.** (2018). Model organism  
829 data evolving in support of translational medicine. *Lab Anim. (NY)* **47**, 277–289.

830 **Hun, M., Ramshaw, J., Chidgey, A. P., Barsanti, M., Wong, K. and Werkmeister, J.** (2016).  
831 Native thymic extracellular matrix improves in vivo thymic organoid T cell output, and  
832 drives in vitro thymic epithelial cell differentiation. *Biomaterials* **118**, 1–15.

833 **Irla, M., Hollander, G. and Reith, W.** (2010). Control of central self-tolerance induction by  
834 autoreactive CD4+ thymocytes. *Trends Immunol.* **31**, 71–79.

835 **James, K. D., Jenkinson, W. E. and Anderson, G.** (2021). Non-Epithelial Stromal Cells in  
836 Thymus Development and Function. *Front. Immunol.* **12**, 1–13.

837 **Jenkinson, E. J., Anderson, G. and Owen, J. J. T.** (1992). Studies on T cell maturation on  
838 defined thymic stromal cell populations in vitro. *J. Exp. Med.* **176**, 845–853.

839 **Kadouri, N., Nevo, S., Goldfarb, Y. and Abramson, J.** (2020). Thymic epithelial cell  
840 heterogeneity: TEC by TEC. *Nat. Rev. Immunol.* **20**, 239–253.

841 **Kernfeld, E. M., Genga, R. M. J., Neherin, K., Magaletta, M. E., Xu, P. and Maehr, R.** (2018).  
842 A Single-Cell Transcriptomic Atlas of Thymus Organogenesis Resolves Cell Types and  
843 Developmental Maturation. *Immunity* **48**, 1258–1270.e6.

844 **Kim, S., Shah, S. B., Graney, P. L. and Singh, A.** (2019). Multiscale engineering of immune  
845 cells and lymphoid organs. *Nat. Rev. Mater.* **4**, 355–378.

846 **Klein, F., Veiga-Villauriz, C., Börsch, A., Maio, S., Palmer, S., Dhalla, F., Handel, A. E.,**  
847 **Zuklys, S., Calvo-Asensio, I., Musette, L., et al.** (2023). Combined multidimensional  
848 single-cell protein and RNA profiling dissects the cellular and functional heterogeneity of  
849 thymic epithelial cells. *Nat. Commun.* **14**, 4071.

850 **Lai, L. and Jin, J.** (2009). Generation of thymic epithelial cell progenitors by mouse embryonic  
851 stem cells. *Stem Cells* **27**, 3012–3020.

852 **Lai, A. Y. and Kondo, M.** (2007). Identification of a bone marrow precursor of the earliest  
853 thymocytes in adult mouse. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 6311–6316.

854 **Lavaert, M., Liang, K. L., Vandamme, N., Park, J. E., Roels, J., Kowalczyk, M. S., Li, B.,**  
855 **Ashenberg, O., Tabaka, M., Dionne, D., et al.** (2020). Integrated scRNA-Seq Identifies  
856 Human Postnatal Thymus Seeding Progenitors and Regulatory Dynamics of  
857 Differentiating Immature Thymocytes. *Immunity* **52**, 1088–1104.e6.

858 **Lepletier, A., Hun, M. L., Hammett, M. V., Wong, K., Naeem, H., Hedger, M., Loveland, K.**  
859 **and Chidgey, A. P.** (2019). Interplay between Follistatin, Activin A, and BMP4 Signaling  
860 Regulates Postnatal Thymic Epithelial Progenitor Cell Differentiation during Aging. *Cell*  
861 *Rep.* **27**, 3887–3901.e4.

862 **Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P. and Tamayo, P.**  
863 (2015). The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst.* **1**,  
864 417–425.

865 Luis, T. C., Luc, S., Mizukami, T., Boukarabila, H., Thongjuea, S., Woll, P. S., Azzoni, E.,  
866 Giustacchini, A., Lutteropp, M., Bouriez-Jones, T., et al. (2016). Initial seeding of the  
867 embryonic thymus by immune-restricted lympho-myeloid progenitors. *Nat. Immunol.* **17**,  
868 1424–1435.

869 Mangiafico, S. S. (2016). SUMMARY AND ANALYSIS OF EXTENSION PROGRAM  
870 EVALUATION IN R.

871 Meireles, C., Ribeiro, A. R., Pinto, R. D., Leitão, C., Rodrigues, P. M. and Alves, N. L.  
872 (2017). Thymic crosstalk restrains the pool of cortical thymic epithelial cells with  
873 progenitor properties. *Eur. J. Immunol.* **47**, 958–969.

874 Mingueneau, M., Kreslavsky, T., Gray, D., Heng, T., Cruse, R., Ericson, J., Bendall, S.,  
875 Spitzer, M. H., Nolan, G. P., Kobayashi, K., et al. (2013). The transcriptional landscape  
876 of  $\alpha\beta$  T cell differentiation. *Nat. Immunol.* **14**, 619–632.

877 Mohtashami, M. and Zúñiga-Pflücker, J. C. (2006). Cutting Edge: Three-Dimensional  
878 Architecture of the Thymus Is Required to Maintain Delta-Like Expression Necessary for  
879 Inducing T Cell Development. *J. Immunol.* **176**, 730–734.

880 Montel-Hagen, A., Sun, V., Casero, D., Tsai, S., Zampieri, A., Jackson, N., Li, S., Lopez,  
881 S., Zhu, Y., Chick, B., et al. (2020). In Vitro Recapitulation of Murine Thymopoiesis from  
882 Single Hematopoietic Stem Cells. *Cell Rep.* **33**, 108320.

883 Murtagh, F. (1987). Multivariate Data Analysis with Fortran, C and Java Code.

884 Nusser, A., Sagar, Swann, J. B., Krauth, B., Diekhoff, D., Calderon, L., Happe, C., Grün,  
885 D. and Boehm, T. (2022). Developmental dynamics of two bipotent thymic epithelial  
886 progenitor types. *Nature* **606**, 165–171.

887 Owen, J. J. T. and Ritter, M. A. (1969). Tissue interaction in the development of thymus  
888 lymphocytes. *J. Exp. Med.* **129**, 431–442.

889 Parent, A. V., Russ, H. A., Khan, I. S., Laflam, T. N., Metzger, T. C., Anderson, M. S. and  
890 Hebrok, M. (2013). Generation of functional thymic epithelium from human embryonic  
891 stem cells that supports host T cell development. *Cell Stem Cell* **13**, 219–229.

892 Park, J. E., Botting, R. A., Conde, C. D., Popescu, D. M., Lavaert, M., Kunz, D. J., Goh, I.,  
893 Stephenson, E., Ragazzini, R., Tuck, E., et al. (2020). A cell atlas of human thymic  
894 development defines T cell repertoire formation. *Science* (80-. ). **367**,.

895 Poznansky, M. C., Evans, R. H., Foxall, R. B., Olszak, I. T., Piascik, A. H., Hartman, K. E.,  
896 Brander, C., Meyer, T. H., Pykett, M. J., Chabner, K. T., et al. (2000). Efficient  
897 generation of human T cells from a tissue-engineered thymic organoid. *Nat. Biotechnol.*  
898 **18**, 729–734.

899 Purwada, A. and Singh, A. (2017). Immuno-engineered organoids for regulating the kinetics  
900 of B-cell development and antibody production. *Nat. Protoc.* **12**, 168–182.

901 Ramos, S. A., Morton, J. J., Yadav, P., Reed, B., Alizadeh, S. I., Shilleh, A. H., Perrenoud,  
902 L., Jagers, J., Kappler, J., Jimeno, A., et al. (2022). Generation of functional human  
903 thymic cells from induced pluripotent stem cells. *J. Allergy Clin. Immunol.* **149**, 767–  
904 781.e6.

905 Reiner, A., Yekutieli, D. and Benjamini, Y. (2003). Identifying differentially expressed genes  
906 using false discovery rate controlling procedures. *Bioinformatics* **19**, 368–375.

907 Robinson, M. D., McCarthy, D. J. and Smyth, G. K. (2010). edgeR : a Bioconductor package  
908 for differential expression analysis of digital gene expression data. *Bioinformatics* **26**,  
909 139–140.

910 Rossi, G., Manfrin, A. and Lutolf, M. P. (2018). Progress and potential in organoid research.  
911 *Nat. Rev. Genet.* **19**, 671–687.

912 Rothenberg, E. V. (2021). Single-cell insights into the hematopoietic generation of T-  
913 lymphocyte precursors in mouse and human. *Exp. Hematol.* **95**, 1–12.

914 Seet, C. S., He, C., Bethune, M. T., Li, S., Chick, B., Gschweng, E. H., Zhu, Y., Kim, K.,  
915 Kohn, D. B., Baltimore, D., et al. (2017). Generation of mature T cells from human  
916 hematopoietic stem and progenitor cells in artificial thymic organoids. *Nat. Methods* **14**,  
917 521–530.

918 Sheridan, J. M., Taoudi, S., Medvinsky, A. and Blackburn, C. C. (2009). A Novel Method  
919 for the Generation of Reaggregated Organotypic Cultures That Permits Juxtaposition of

920      Defined Cell Populations. *Genesis* **351**, 346–351.

921      **Smyth, G. K., Ritchie, M. E., Law, C. W., Alhamdoosh, M., Su, S., Dong, X. and Tian, L.**  
 922      (2018). RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR.  
 923      *F1000Research* **5**.

924      **Steier, Z., Aylard, D. A., McIntyre, L. L., Baldwin, I., Jeong Yoon Kim, E., Lutes, L. K.,**  
 925      **Ergen, C., Huang, T.-S., Robey, E. A., Yosef, N., et al.** (2023). Single-cell multi-omic  
 926      analysis of thymocyte development reveals drivers of CD4/CD8 lineage commitment. *Nat.*  
 927      *im* **24**, 1579–1590.

928      **Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A.,**  
 929      **Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al.** (2005). Gene set  
 930      enrichment analysis: A knowledge-based approach for interpreting genome-wide  
 931      expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550.

932      **Sun, X., Xu, J., Lu, H., Liu, W., Miao, Z., Sui, X., Liu, H., Su, L., Du, W., He, Q., et al.** (2013).  
 933      Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-  
 934      like cells reconstitutes the thymic microenvironment in vivo. *Cell Stem Cell* **13**, 230–236.


935      **Wagar, L. E., Salahudeen, A., Constantz, C. M., Wendel, B. S., Lyons, M. M., Mallajosyula,**  
 936      **V., Jatt, L. P., Adamska, J. Z., Blum, L. K., Gupta, N., et al.** (2021). Modeling human  
 937      adaptive immune responses with tonsil organoids. *Nat. Med.* **27**, 125–135.


938      **Wong, K., Lister, N. L., Barsanti, M., Lim, J. M. C., Hammett, M. V., Khong, D. M., Siatskas,**  
 939      **C., Gray, D. H. D., Boyd, R. L. and Chidgey, A. P.** (2014). Multilineage potential and  
 940      self-renewal define an epithelial progenitor cell population in the adult thymus. *Cell Rep.*  
 941      **8**, 1198–1209.

942      **Zhou, W., Yui, M. A., Williams, B. A., Yun, J., Wold, B. J., Cai, L., Rothenberg, E. V, Zhou,**  
 943      **W., Yui, M. A., Williams, B. A., et al.** (2019). Single-Cell Analysis Reveals Regulatory  
 944      Gene Expression Dynamics Leading to Lineage Commitment in Early T Cell Development  
 945      Article Single-Cell Analysis Reveals Regulatory Gene Expression Dynamics Leading to  
 946      Lineage Commitment in Early T Cell Development. *Cell Syst.* **9**, 321–337.e9.

947      **Žuklys, S., Handel, A., Zhanybekova, S., Govani, F., Keller, M., Maio, S., E Mayer, C., Ying**  
 948      **Teh, H., Hafen, K., Gallone, G., et al.** (2016). Foxn1 regulates key target genes essential  
 949      for T cell development in postnatal thymic epithelial cells. *Nat. Immunol.* **17**, 1206–1215.

952 **Supplementary information**





**Fig. S2. Generation and analysis of ORFTOCs and control conditions.** (A) Flow cytometry plots showing the developmental stage (DN) of thymocytes in E13.5 thymi. (B) Flow cytometry plots demonstrating the gating strategy used to analyze thymocyte development in ORFTOCs and control conditions. The last plot highlights the CD45+ Lin- population in ORFTOCs at D6. (C-D) Flow cytometry plots representing the CD45+ Lineage- population in control reaggregates with MEFs and the EpCAM-depleted fraction of cells from E13.5 thymi (C) and in FTOC controls (D) at D6. (E) Flow cytometry plot showing T cell development in D13 ORFTOCs made with adult DN1 as T cell input population. Gating strategy is indicated on the left. (F) Flow cytometry plots representing the CD3ε+ TCRβ+ population in D13 ORFTOCs, and its division into CD4SP and CD8SP T cell lineages, with gating strategies indicated on the left of each plot. (G) Flow cytometry plot showing the CD3ε+ TCRβ+ population in D13 FTOC controls. Gating strategy is as in F (left). (H) Percentage of CD4SP and CD8SP within the CD3ε+ TCRβ+ population, at D6 and D13, for both ORFTOCs and FTOC controls. ns:  $P > 0.05$  (Brown-Forsythe ANOVA test for both CD4SP and CD8SP with Dunnet's T3 multiple comparisons test;  $n = 5$  for all ORFTOC populations and time,  $n = 10$  for FTOC populations at D6 and  $n = 6$  for FTOC populations at D13, from 5 independent experiments). Graph represents individual datapoints with mean + SD.

967

968

969

970

971  
972

972

073

973

975

976

977

978

979


980

981

982


983

984



985  
986  
987  
988  
989  
990  
991

**Fig. S3. Single-cell transcriptomic characterization of ORFTOCs and FTOCs. (A)** UMAP showing the different epithelial clusters. **(B)** UMAPs highlighting characteristic marker expression for each of the epithelial clusters. **(C)** UMAP showing the different immune clusters. **(D)** Dot plot summarizing the expression of characteristic markers of T cell development for the different clusters.



992  
993

**Fig. S4. Analysis of ORFTOC grafts and comparison to controls. (A - F)** Flow cytometry plots showing the gating strategy to analyze grafts. ORFTOCs (CD45.2) were grafted under the kidney capsule of CD45.1 hosts. Live, single, Lineage negative (CD11b, CD11c, Gr1, Ter119, DX5, NK-1.1, MHCII, F4/80) cells were gated for CD45.1 positivity (A) and TCRγδ negative T cells were further analyzed (B). CD25 and CD71 expression on CD24+ DN cells were used to enumerate DN3a, DN3b and DN4 subsets, quantified in (C) for the different conditions. β-selection occurs at the DN3a to DN3b transition. CD69 expression identifies cells undergoing positive selection and is quantified in (D) for the different conditions. Gating on the TCRαβ+ population, mature (M1 and M2) CD4SP and CD8SP T cells are quantified in E for the different conditions. Within the M2 population, CD4 regulatory T cells (CD4reg) are quantified in F for the different conditions. For all bar graphs, only significant differences are indicated with stars. \* P = 0.0381 (DN3a ORFTOC vs thymus), \*\*\* P = 0.0009 (DN3b ORFTOC vs thymus), \* P = 0.0116 (DN3b FTOC vs thymus), \* P = 0.0373 (CD69 FTOC vs thymus), ns: P > 0.05 (one-way ANOVA for each subpopulation between conditions, n = 3 grafts/mice for each condition). Bar graphs represent mean and SD, with individual datapoints displayed as circles. (G) Hematoxylin and eosin (H&E) staining of ORFTOC and FTOC grafts.

1009

1010 **Movie 1. Thymic epithelial organoid establishment.** One week time-lapse showing the  
1011 development of thymic epithelial organoids starting from sorted single thymic epithelial cells  
1012 seeded in Matrigel and cultured in defined conditions.  
1013